leukemia Mar 8, 2023 Blood-Based MRD Testing Identifies AML Patients at Risk of Relapse After Stem Cell Transplant Feb 27, 2023 European Medicine Agency's CHMP Recommends Tibsovo for IDH1-Mutated AML, Bile Duct Cancer Feb 9, 2023 Kura Oncology Begins Phase II Ziftomenib Trial in NPM1-Mutant Acute Myeloid Leukemia Feb 8, 2023 Actinium Pharmaceuticals, NCI Ink Research Agreement on Targeted Radiopharmaceutical Feb 1, 2023 Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Jan 31, 2023 Aptose Biosciences Begins Expansion Trial of Tuspetinib in TP53, FLT3-Mutant AML Jan 26, 2023 BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Jan 5, 2023 Theseus Reveals Development Milestones for its Precision Oncology Programs in 2023 Jan 5, 2023 Pharmacotyping Links Childhood Leukemia Subtypes to Treatment Response Dec 22, 2022 OneChain Immunotherapeutics to Launch CD1a-Targeting CAR T-Cell Therapy Trial in T-Cell Leukemia Dec 19, 2022 Ordaōs, Yatiri Bio Ink Deal to Discover, Develop More Personalized Drugs for AML Dec 19, 2022 SeekIn Receives CE-IVD Mark for Leukemia Cancer Mutation Detection Kit Dec 15, 2022 Leukemia Patients See Survival Benefit With Integrated Functional Drug, Molecular Testing Approach Premium Dec 13, 2022 Amgen to Seek Blincyto Approval in MRD-Negative ALL Following Positive Phase III Results Premium Dec 13, 2022 Envisagenics, Cancer Research UK, Queen Mary University Collaborate on AML Drug R&D Dec 11, 2022 Polygenic Risk Score Shows Potential in Personalizing Chemotherapy for Pediatric AML Patients Premium Dec 11, 2022 Menin Inhibitors Show Activity in AML With NPM1, KMT2A Alterations Premium Dec 8, 2022 Daiichi Sankyo Transfers Rights to Market Yescarta in Japan to Gilead Sciences Dec 2, 2022 FDA Approves Rigel Pharmaceuticals' Rezlidhia for IDH1-Mutant AML Nov 17, 2022 Takeda to Discuss Positive Phase III Iclusig Data in Upfront ALL With Regulators Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma